LBA81 Updated Efficacy and Safety Results from Phase III GLOW Study Evaluating Zolbetuximab + CAPOX As First-Line (1L) Treatment for Patients with Claudin-18 Isoform 2-Positive (CLDN18.2+), HER2−, Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mg/gej) Adenocarcinoma

F. Lordick,M. A. Shah,K. Shitara,J. A. Ajani,Y-J. Bang,P. C. Enzinger,D. H. Ilson,E. van Cutsem,J. Gallego Plazas,J. Huang,L. Shen,S. C. Oh,P. Sunpaweravong,H. H. F. Soo,H. M. Turk,J. W. Park,D. Moran,P. Bhattacharya,Y. J. Cao,R-H. Xu

DOI: https://doi.org/10.1016/j.annonc.2023.10.082

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:The phase 3 GLOW study showed statistically significant improvement with 1L zolbetuximab + capecitabine + oxaliplatin (CAPOX) vs placebo (PBO) + CAPOX in PFS (final; median 8.2 vs 6.8 mo, HR 0.69 [95% CI 0.54, 0.87], P = 0.0007) and OS (interim; median 14.4 vs 12.2 mo, HR 0.77 [95% CI 0.62, 0.97], P = 0.0118) in pts with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma. We present an updated efficacy and safety analysis with 8.7 mo additional follow-up from the primary analysis. Pts were randomly assigned 1:1 to zolbetuximab IV 800 mg/m2 (cycle 1, day [D] 1) followed by 600 mg/m2 (every 3 weeks) + CAPOX (oral capecitabine BID on D1–14 and oxaliplatin IV on D1) for eight 21-day cycles or to PBO + CAPOX; pts without progressive disease (PD) continued beyond cycle 8 with zolbetuximab or PBO, + capecitabine at investigator's discretion, until PD or discontinuation criteria were met. Primary endpoint was PFS per RECIST v1.1 by IRC; OS was a key secondary endpoint. At data cutoff (June 29, 2023), 507 pts were assigned to zolbetuximab + CAPOX (n = 254) or PBO + CAPOX (n = 253). In zolbetuximab vs PBO arms, median follow-up was 17.8 vs 15.1 mo for PFS and 26.1 vs 26.2 mo for OS, respectively. Median PFS in zolbetuximab vs PBO arms was 8.3 vs 6.8 mo (HR 0.68 [95% CI 0.55, 0.85], P = 0.0004). Median OS in zolbetuximab vs PBO arms was 14.3 vs 12.2 mo (HR 0.77 [95% CI 0.62, 0.95], P = 0.0079); 24-mo OS rate was 28.3% vs 18.8%, with follow-up ongoing through final analyses. Most common TEAEs with zolbetuximab + CAPOX were nausea (zolbetuximab arm: 68.9% vs PBO arm: 50.2%), vomiting (66.1% vs 31.3%), and decreased appetite (41.3% vs 34.5%); incidences of serious TEAEs were similar between arms (48.0% vs 50.6%). Zolbetuximab + CAPOX continued to demonstrate statistically significant improvement in PFS and OS compared with PBO + CAPOX, with no new safety signals, supporting zolbetuximab + CAPOX as a potential new option for 1L treatment of patients with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma.